New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 28, 2014
07:17 EDTINCYIncyte to present data from multiple cancer programs at ASCO meeting
Incyte will present new data from its lead cancer programs focused on onco-inflammation, immuno-oncology and myeloproliferative neoplasms at the 50th Annual Meeting of the American Society of Clinical Oncology from May 30 to June 3. Data to be presented include full results from RECAP, the Phase II trial of ruxolitinib in combination with capecitabine in metastatic pancreatic cancer. Topline results showed an overall survival benefit in a pre-specified subgroup analysis of patients. Also being presented are preliminary findings from a Phase I/II study of Incyte’s IDO1 inhibitor, INCB24360, in combination with ipilimumab in patients with metastatic melanoma, designed to examine potential synergy with other cancer immunotherapies. Full results will be presented from the pivotal Phase III RESPONSE trial of ruxolitinib in patients with uncontrolled polycythemia vera, the first Phase III study to evaluate a JAK inhibitor as a treatment for patients with PV, which met its primary endpoint.
News For INCY From The Last 14 Days
Check below for free stories on INCY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 17, 2014
08:44 EDTINCYIncyte weakness creates buying opportunity, says Argus
Subscribe for More Information
September 12, 2014
13:48 EDTINCYArray names Sandor Chief Medical Officer to replace Needle
Subscribe for More Information
September 11, 2014
09:18 EDTINCYIncyte management to meet with Leerink
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use